Our Mission

We collaborate with thought leaders across the industry to inform, debate and advance policies that promote access to high-quality, affordable health care.

Our Vision
To be a leading advocacy voice for access to high-quality, equitable, and affordable health care in Idaho, Oregon, Utah, and Washington.

Learn more

What we do

Thought Partnership

We create partnerships to collectively influence emerging health care trends and policies.

Policy Development

We work to develop policy solutions to emerging health care issues.

Legislative Education

We provide resources for engagement with policymakers to educate them on policy solutions.

Our work

The Regence Health Policy Center (RHPC) creates research-driven data and insights to inform health care policies across our four market states. Our goal is to contribute credible information through white papers, policy analyses, events, timely research, and insights from Regence's four Blues plans.

Publications

High Value Care

January 16th, 2024

Utah Leaders Discuss Affordability at UHPP’s Annual Conference

Regence Health Policy Center sponsored The Utah Health Policy Project’s (UHPP) annual conference earlier this month, bringing together lawmakers and health care leaders to tackle pressing issues in behavioral health access and health care affordability.

Personalization & Engagement

November 30th, 2023

2023 Oregon State of Reform Health Policy Conference

Portland again played host to Oregon State of Reform’s annual health policy conference. Key themes included behavioral health access and workforce, data integration and interoperability, social drivers of health, and state-level Medicaid innovations.

High Value Care

November 21st, 2023

Addressing Rising Health Care Costs with State Lawmakers at CSG West

The Regence Health Policy Center convened a panel on provider affordability, featuring insights from AHIP, the National Academy for State Health Policy (NASHP), and Washington State Representative Nicole Macri. The panel spotlighted obstacles to affordability including provider acquired drug markups, consolidation, anti-competitive contracting terms, and exorbitant facility fees.